MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584768 | Name: Mofarotene

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mofarotene is an antineoplastic agent.

Chemical Structure

Mofarotene
Mofarotene
CAS#125533-88-2

Theoretical Analysis

MedKoo Cat#: 584768

Name: Mofarotene

CAS#: 125533-88-2

Chemical Formula: C29H39NO2

Exact Mass: 433.2981

Molecular Weight: 433.64

Elemental Analysis: C, 80.33; H, 9.07; N, 3.23; O, 7.38

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Mofarotene
IUPAC/Chemical Name
4-(2-(p-((E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl)phenoxy)ethyl)morpholine
InChi Key
OUQPTBCOEKUHBH-LSDHQDQOSA-N
InChi Code
InChI=1S/C29H39NO2/c1-22(24-8-11-26-27(21-24)29(4,5)13-12-28(26,2)3)20-23-6-9-25(10-7-23)32-19-16-30-14-17-31-18-15-30/h6-11,20-21H,12-19H2,1-5H3/b22-20+
SMILES Code
C/C(C1=CC=C2C(C)(C)CCC(C)(C)C2=C1)=C\C3=CC=C(OCCN4CCOCC4)C=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 433.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Lave T, Schmitt-Hoffmann AH, Coassolo P, Valles B, Ubeaud G, Ba B, Brandt R, Chou RC. A new extrapolation method from animals to man: application to a metabolized compound, mofarotene. Life Sci. 1995;56(26):PL473-8. PubMed PMID: 7791515. 2: Helige C, Hofmann-Wellenhof R, Fink-Puches R, Smolle J. Mofarotene-induced inhibition of melanoma cell motility by increasing vinculin-containing focal contacts. Melanoma Res. 2004 Dec;14(6):547-54. PubMed PMID: 15577329. 3: Eliason JF, Baumgartner M, Yoshikubo T, Hirabayashi Y, Mitsui H, Inoue T. Mofarotene (Ro 40-8757) inhibits hematopoiesis in vitro by preventing maturation from primitive progenitor cells. Blood. 1995 Dec 15;86(12):4516-26. PubMed PMID: 8541541. 4: Cariati R, Zancai P, Righetti E, Rizzo S, De Rossi A, Boiocchi M, Dolcetti R. Inhibition of oxidative phosphorylation underlies the antiproliferative and proapoptotic effects of mofarotene (Ro 40-8757) in Burkitt's lymphoma cells. Oncogene. 2003 Feb 13;22(6):906-18. PubMed PMID: 12584570. 5: Vallès B, Ba B, Wyss R, Reigner B, Coassolo P. In vivo and in vitro kinetics of mofarotene in mouse, rat, dog and man. Eur J Drug Metab Pharmacokinet. 1995 Jan-Mar;20(1):49-53. PubMed PMID: 7588994. 6: Kawa S, Nikaido T, Aoki Y, Zhai Y, Kumagaya T, Furihata K, Fujii S, Kiyosawa K. Arotinoid mofarotene (RO40-8757) up-regulates p21 and p27 during growth inhibition of pancreatic cancer cell lines. Int J Cancer. 1997 Sep 4;72(5):906-11. PubMed PMID: 9311612. 7: Uchida T, Inagaki N, Furuichi Y, Eliason JF. Down-regulation of mitochondrial gene expression by the anti-tumor arotinoid mofarotene (Ro 40-8757). Int J Cancer. 1994 Sep 15;58(6):891-7. PubMed PMID: 7927884. 8: Wyss R, Bucheli F, Hess B. Determination of the arotinoid mofarotene in human, rat and dog plasma by high-performance liquid chromatography with automated column switching and ultraviolet detection. J Chromatogr A. 1996 Apr 5;729(1-2):315-22. PubMed PMID: 9004956. 9: Valles B, Schiller CD, Coassolo P, De Sousa G, Wyss R, Jaeck D, Viger-Chougnet A, Rahmani R. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation. Drug Metab Dispos. 1995 Oct;23(10):1051-7. PubMed PMID: 8654192. 10: Tanaka T, Makita H, Ohnishi M, Mori H, Satoh K, Hara A. Inhibition of oral carcinogenesis by the arotinoid mofarotene (Ro 40-8757) in male F344 rats. Carcinogenesis. 1995 Aug;16(8):1903-7. PubMed PMID: 7634421. 11: Teelmann K, Tsukaguchi T, Klaus M, Eliason JF. Comparison of the therapeutic effects of a new arotinoid, Ro 40-8757, and all-trans- and 13-cis-retinoic acids on rat breast cancer. Cancer Res. 1993 May 15;53(10 Suppl):2319-25. PubMed PMID: 8485719. 12: Louvet C, Empereur S, Fagot D, Forgue-Lafitte E, Chastre E, Zimber A, Mester J, Gespach C. The arotinoid Ro 40-8757 has antiproliferative effects in drug-resistant human colon and breast cancer cell lines in vitro. Cancer Lett. 1994 Sep 30;85(1):83-6. PubMed PMID: 7923106. 13: Pomponi F, Cariati R, Zancai P, De Paoli P, Rizzo S, Tedeschi RM, Pivetta B, De Vita S, Boiocchi M, Dolcetti R. Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. Blood. 1996 Oct 15;88(8):3147-59. PubMed PMID: 8874215. 14: Eliason JF, Kaufmann F, Tanaka T, Tsukaguchi T. Anti-proliferative effects of the arotinoid Ro 40-8757 on human cancer cell lines in vitro. Br J Cancer. 1993 Jun;67(6):1293-8. PubMed PMID: 8390284; PubMed Central PMCID: PMC1968519. 15: López-Boado YS, Klaus M, Dawson MI, López-Otín C. Retinoic acid-induced expression of apolipoprotein D and concomitant growth arrest in human breast cancer cells are mediated through a retinoic acid receptor RARalpha-dependent signaling pathway. J Biol Chem. 1996 Dec 13;271(50):32105-11. PubMed PMID: 8943263. 16: Arnold A, Kowaleski B, Tozer R, Hirte H. The arotinoids: early clinical experience and discussion of future development. Leukemia. 1994;8 Suppl 3:S42-9. Review. PubMed PMID: 7808024. 17: Eliason JF, Inoue T, Kubota A, Horii I, Hartmann D. The anti-tumor arotinoid Ro 40-8757 protects bone marrow from the toxic effects of 5-fluorouracil. Int J Cancer. 1994 Apr 15;57(2):192-7. PubMed PMID: 8157357. 18: Inoue T, Horii I. Aromatic retinoid Ro 40-8757 reduces immunotoxicities of cyclophosphamide as revealed by immunohistochemical staining of lymphoid tissues and general pathologic examinations. J Toxicol Sci. 2000 Aug;25(3):189-98. PubMed PMID: 10987126. 19: Louvet C, Djelloul S, Forgue-Lafitte ME, Mester J, Zimber A, Gespach C. Antiproliferative effects of the arotinoid Ro 40-8757 in human gastrointestinal and pancreatic cancer cell lines: combinations with 5-fluorouracil and interferon-alpha. Br J Cancer. 1996 Aug;74(3):394-9. PubMed PMID: 8695354; PubMed Central PMCID: PMC2074625. 20: Rao GN, Ney E, Herbert RA. Effect of retinoid analogues on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res Treat. 1998 Apr;48(3):265-71. PubMed PMID: 9598873.